Al-Kadhimi, Zaid http://orcid.org/0000-0002-6820-8786
Pirruccello, Samuel
Gul, Zartash
Maness-Harris, Lori
Bhatt, Vijaya Raj http://orcid.org/0000-0003-2513-0533
Gundabolu, Krishna
Yuan, Jane
Lunning, Matthew
Bociek, Gregory
D’Angelo, Christopher
Kallam, Avyakta
Armitage, James
Abdullah, Khansa
Hunter, Angela
Mccaslin, Sarah
Lyden, Elizabeth
Smith, Lynnette
Callahan, Michael II http://orcid.org/0000-0002-1625-5126
Cole, Kathryn
Hinrichs, Steven
Talmadge, James
Vose, Julie http://orcid.org/0000-0003-1015-7434
Funding for this research was provided by:
University of Nebraska Foundation
Article History
Received: 11 May 2022
Revised: 23 July 2022
Accepted: 27 July 2022
First Online: 11 August 2022
Competing interests
: VRB reports participating in Safety Monitoring Committee for Protagonist, and receiving consulting fees from Genentech, Incyte, Servier Pharmaceuticals LLC, and Abbvie, research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Oncoceutics for a trial. KG consulting: Bayer consumer care, CTI biopharma, BMS, Blueprint Medicines, Jazz Pharmaceuticals, BioMarin Pharmaceuticals. Institutional funding: Samus therapeutics, Incyte, Pfizer, Autolus therapeutics. JV Consulting: Morphosys, Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Daiichi Sankyo, Johnson and Johnson, Pharmacyclics, Genentech. Research: Loxo Pharma, Novartis, Kite.